前言胃癌是全球最常见的恶性肿瘤之一，表现出显著的分子和表型异质性。2020年胃癌新增病例1089103例，死亡768793例，是全球第五大常见癌症和第四大癌症死亡原因。胃癌的流行病学分布因性别和地理区域而异，男性的发病率是女性的两倍，东亚和东欧的发病 ...

EGF receptor (EGFR) and HER2 are two members of the ErbB/HER-family of tyrosine-kinase receptors that are frequently altered in breast cancer and several other malignancies, which inspired the ...

HER3的表达在EGFR突变的NSCLC患者中普遍增强，尤其是在EGFR-TKI治疗后，其过表达现象更为显著。研究显示，HER3-DXd作为一种以HER3为靶点的抗体药物偶联物（ADC），在EGFR-TKI和铂类化疗后经过治疗的患者中展现出良好的初步疗效。 一项II期HERTHENA-Lung01研究表明 ...

The DXd ADC portfolio currently consists of Enhertu, a HER2 directed ADC, and datopotamab deruxtecan (Dato-DXd), a TROP2 directed ADC, which are being jointly developed and commercialized globally ...

Enhertu, administered as an intravenous (IV) infusion, is specifically directed at HER2, a tyrosine kinase receptor growth ... shared positive results from a late-stage trial of their HER3-directed ...

Expert Rev Mol Diagn. 2008;8(4):417-434. Interestingly, cancers that co-overexpress EGFR and HER2 have a worse clinical outcome than those overexpressing either receptor alone. There is therefore ...

The agency did not request any additional clinical data, according to Merus. In its BLA, Merus submitted data from the Phase I/II eNRGy trial, in which it evaluated the safety and anti-tumor activity ...